Stereotactic Ablative Radiotherapy (SABR) or Stereotactic Radiosurgery (SRS) for oligometastatic cancer or oligoprogression of metastatic cancer is supported by an expanding body of evidence in the literature. The degree of uptake of these techniques, supplanting traditional and potentially less resource-intensive techniques in this patient population, would be of interest to clinicians and administrators alike. A review of provincial date for Ontario, Canada (population ∼ 15 million) was performed to quantify the use of SABR/SRS to metastases either in the brain or elsewhere in the body. Data was obtained from a new (April 2022) activity-based hospital funding model, responsible for ALL radiation treatment remuneration at all facilities across the province (i.e., single payer system). Funding is triggered when a patient is treated as per 1 or more of the ∼270 provincial radiation protocols, defined as a "protocol instance". Protocols were developed by clinicians across Ontario according to a consensus-based iterative process, considering provincial, national and international guidelines and/or evidence-based practice. Prerequisite information for remuneration included (but was not limited to): patient demographics, identification of whether a primary tumor or metastasis(es) was treated, protocol, radiation technique, dose/fractionation, and encounter dates. Submission of data was performed by the 17 hospitals who provide radiation services and logic checked centrally by the provincial cancer agency following submission. Validation of data is performed by ongoing iterative processes. From April 1 to November 30, 2022, a total of 31,916 radiation protocol instances were funded for 27,298 patients. Of these, 4,156 (13%) were SABR/SRS protocols. When only treatment to metastases were considered, the total number of SABR/SRS protocol instances was 3,024 (9.5% of total) and 29.4% of the total number of protocol instances delivered to metastases (10,271). The 29.4% was split further as 1567 protocol instances (15.3%) to brain metastases and 1457 protocol instances elsewhere in the body, most often to lung (3.9%), spine (3.4%), non-spine bone (2.2%) and liver (1.7%), with a further 2.9% to unspecified extra-cranial metastases. Data for all 17 Ontario treatment facilities revealed a range of SABR/SRS usage for metastases from 1.8 to 59.8% (median 23.2%, IQ range 16.9%). On review of recently submitted data, nearly 1/3 of all radiation treatments to metastases in Ontario are delivered using a SABR/SRS technique. There is wide regional variation in the use of these techniques. Reasons for this variation require further investigation.